Doctronic

Doctronic has raised $40 million in a Series B funding round co-led by Abstract and Lightspeed Venture Partners, with additional participation from Union Square Ventures, Seven Stars, Mantis, and Tusk Ventures. This funding, the company's third round in under a year, increases its total funding to over $65 million. The company focuses on AI-based prescription renewal and autonomous clinical care solutions.

New York-based Doctronic has raised $40 million in a Series B funding round co-led by Abstract and Lightspeed Venture Partners. The company, which claims to be the first AI system legally allowed to practice medicine in the U.S., aims to streamline prescription renewals through AI, allowing patients to receive medication refills without a physician. Doctronic has raised over $65 million to date and has seen significant growth, achieving an 8-figure annualized revenue and a nearly tripled repeat patient rate.